Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cell ; 148 (2012), 4. - S. 727-738. - ISSN 0092-8674. - eISSN 1097-4172
- Klassifikation
-
Biowissenschaften, Biologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Konstanz
- (wer)
-
Bibliothek der Universität Konstanz
- (wann)
-
2012
- Urheber
-
Huber, Eva M.
Basler, Michael
Schwab, Ricarda
Heinemeyer, Wolfgang
Kirk, Christopher J.
Groettrup, Marcus
Groll, Michael
- URN
-
urn:nbn:de:bsz:352-195339
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Huber, Eva M.
- Basler, Michael
- Schwab, Ricarda
- Heinemeyer, Wolfgang
- Kirk, Christopher J.
- Groettrup, Marcus
- Groll, Michael
- Bibliothek der Universität Konstanz
Entstanden
- 2012
Ähnliche Objekte (12)
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
The ubiquitin-like modifier FAT10 : much more than a proteasome-targeting signal
The Proteasome, a New Target for Cancer Therapy
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins
The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition
Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L
Interferon-γ inducible exchanges of 20S proteasome active site subunits : why?
The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition
Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome
Pronounced up-regulation of the PA28α/β proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit
The ubiquitin-like modifier FAT10 in cancer development
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
The ubiquitin-like modifier FAT10 : much more than a proteasome-targeting signal
The Proteasome, a New Target for Cancer Therapy
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins
The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition
Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L
Interferon-γ inducible exchanges of 20S proteasome active site subunits : why?
The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition
Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome
Pronounced up-regulation of the PA28α/β proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit
The ubiquitin-like modifier FAT10 in cancer development
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
The ubiquitin-like modifier FAT10 : much more than a proteasome-targeting signal
The Proteasome, a New Target for Cancer Therapy
Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins
The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition
Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L
Interferon-γ inducible exchanges of 20S proteasome active site subunits : why?
The proteasome regulator PA28α/β can enhance antigen presentation without affecting 20S proteasome subunit composition
Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome
Pronounced up-regulation of the PA28α/β proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation
Prostaglandin E2 inhibits IL-23 and IL-12 production by human monocytes through down-regulation of their common p40 subunit